Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sumatriptan clinical pharmacokinetics

A K Scott1

  • 1Department of Geriatric Medicine, University of Manchester, Salford, England.

Clinical Pharmacokinetics
|November 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ethosuximide: liver enzyme induction and D-glucaric acid excretion.

British journal of clinical pharmacology·2012
Same author

Prescribing in the elderly.

Postgraduate medical journal·1995
Same author

Gender discrimination in the medical community.

Update (Loma Linda University. Ethics Center)·1995
Same author

Stereoisomers and drug toxicity. The value of single stereoisomer therapy.

Drug safety·1993
Same author

The use of cimetidine to reduce dapsone-dependent methaemoglobinaemia in dermatitis herpetiformis patients.

British journal of clinical pharmacology·1992
Same author

Dihydroergotamine: a review of its use in the treatment of migraine and other headaches.

Clinical neuropharmacology·1992
Same journal

Population Pharmacokinetic Modelling of Dolutegravir: A Narrative Review.

Clinical pharmacokinetics·2026
Same journal

Partial Area Under the Curve: A Revelatory Story in Pharmacokinetics.

Clinical pharmacokinetics·2026
Same journal

Informing Sampling Design for Lung Distribution Studies Using a Pulmonary Population Minimal PBPK Model.

Clinical pharmacokinetics·2026
Same journal

Revisited Pharmacokinetic Profiles of Methylprednisolone in Plasma and Urine After Single and Multiple Oral Administrations: Relevance in Sports Drug Testing.

Clinical pharmacokinetics·2026
Same journal

ALBI Grade is a Determinant of Lenvatinib Pharmacokinetics, Efficacy, and Toxicities in Japanese Patients with Hepatocellular Carcinoma.

Clinical pharmacokinetics·2026
Same journal

Quantitative Pharmacology Justifying Ribociclib Dose in Early Breast Cancer.

Clinical pharmacokinetics·2026
See all related articles

Sumatriptan, a serotonin 1 (5-HT1)-like agonist, effectively treats acute migraine. Its pharmacokinetic profile, including rapid absorption and a 2-hour half-life, is generally unaffected by migraine or patient demographics.

Area of Science:

  • Pharmacology
  • Clinical Pharmacy

Background:

  • Sumatriptan is a selective serotonin 1 (5-HT1)-like receptor agonist used for acute migraine treatment.
  • Understanding its pharmacokinetics is crucial for effective clinical application.

Purpose of the Study:

  • To characterize the single-dose pharmacokinetics of sumatriptan.
  • To inform optimal dosing and administration strategies for sumatriptan in migraine management.

Main Methods:

  • Pharmacokinetic analysis of sumatriptan following subcutaneous and oral administration.
  • Assessment of drug absorption, distribution, metabolism, and excretion (ADME) parameters.

Main Results:

  • High bioavailability (96%) via subcutaneous injection; low bioavailability (14%) orally due to first-pass metabolism.

Related Experiment Videos

  • Rapid absorption after subcutaneous injection (peak in 10 min); delayed, multiple peaks orally (75% peak by 45 min).
  • Volume of distribution 170L, rapid clearance, and ~2-hour elimination half-life; major metabolite is an indole acetic acid analogue.

    • Conclusions:

    • Sumatriptan exhibits favorable pharmacokinetics for acute migraine treatment, with route-dependent absorption.
    • Pharmacokinetics are largely unaffected by age, gender, or acute migraine, but caution is advised in hepatic impairment.
    • No significant drug interactions observed with common co-administered medications or alcohol.